Get started
Markets US Stocks Health Technology Pharmaceuticals: Major

AC Immune SA ACIU

ACIU NASDAQ
ACIU
AC Immune SA NASDAQ
See more on advanced chartSee more on advanced chart
 
No trades
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
See more on advanced chartSee more on advanced chart
Overview
News Ideas Financials Technicals

ACIU Chart

Ideas

$ACIU is gonna fall today
ACIU
, 15Short
ACIU: $ACIU is gonna fall today

Pupm&Dump trading strategy idea. $ACIU is rising too much today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $11,85; stop-loss — $12,77; take-profit — $10,02/MOC Do not view this idea as a recommendation for trading or investing. It is...

AC IMMUNE Long Term
ACIU
, 1WLong
ACIU: AC IMMUNE Long Term

-

$ACIU Ac Immune On Breakout Watchlist
ACIU
, 1DLong
ACIU: $ACIU Ac Immune On Breakout Watchlist

ACIU had the potential for a move into the gap this week. RSi crossing Mid-point MACD crossing Zero-line Momentum Above Zero-line 20 & 7 ma's rising and crossing 50ma. Alert set for potential entry above $5.75 Targets $6.30 = 100ma $6.50 = Major Pivot $6.87 = Monthly candle resistance $7.45 = weekly candle resistance

The Fake, Fake and Break
ACIU
, 1D
ACIU: The Fake, Fake and Break

The fake, fake, and break out the example. It's broken the resistance (yellow line)

ACIU hit a long term trend line this month
ACIU
, 60Short
ACIU: ACIU hit a long term trend line this month
05:25

ACIU has been trending upwards for some months now but hit a 2018 trend line so I m looking to short ACIU on a upward pull back if possible.

ACIU 70% PROFIT in 50 days
ACIU
, 1020Long
ACIU: ACIU 70% PROFIT in 50 days

Strength and kickback with a pull down and positive earnings, Conservative at 11.60 ,

$ACIU - Cup and handle on huge volume.
ACIU
, 1DLong
ACIU: $ACIU - Cup and handle on huge volume.

Could run more.

Technicals

Analyst rating

Financials

Valuation
Enterprise Value/EBITDA, TTM —
Enterprise Value, FQ —
Market Cap — Basic —
Number of Employees —
Number of Shareholders —
Price/Earnings, TTM —
Price/Revenue, TTM —
Price/Book Ratio, FY —
Price/Sales Ratio, FY —
Balance Sheet
Current Ratio, FQ —
Debt to Equity, FQ —
Net Debt, FQ —
Quick Ratio, FQ —
Total Assets, FQ —
Total Debt, FQ —
Operating Metrics
Return on Assets, TTM —
Return on Equity, TTM —
Return on Invested Capital, TTM —
Revenue per Employee, TTM —
Price History
Average Volume (10 day) —
Beta - 1 Year —
Price - 52 Week High —
Price - 52 Week Low —
Dividends
Dividends Paid, FY —
Dividends per Share, FY —
Expected Annual Dividends —
Dividends Yield —
Margins
Net Margin, TTM —
Gross Margin, TTM —
Operating Margin, TTM —
Pretax Margin, TTM —
Income Statement
Basic EPS, Net Income —
Earnings per Share, Basic, TTM —
EBITDA, TTM —
Gross Profit, FY —
Last Annual EPS —
Last Annual Revenue, FY —
Net Income, FY —
Total Revenue, FY —
Free Cash Flow, TTM —
More financials

Profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Breaking news

More news